Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists
Identifieur interne : 002F25 ( Main/Corpus ); précédent : 002F24; suivant : 002F26Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists
Auteurs : Frank Andersohn ; Edeltraut GarbeSource :
- Movement Disorders [ 0885-3185 ] ; 2009-01-15.
English descriptors
Abstract
There is growing evidence that the ergot‐derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot‐derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot‐derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot‐derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot‐derived dopamine agonists may not be limited to heart valves. For nonergot‐derived dopamine agonists, no drug safety signals were evident. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22385
Links to Exploration step
ISTEX:18CAB01959EC9E2E746617E00BF56310978DC8D2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists</title><author><name sortKey="Andersohn, Frank" sort="Andersohn, Frank" uniqKey="Andersohn F" first="Frank" last="Andersohn">Frank Andersohn</name><affiliation><mods:affiliation>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name><affiliation><mods:affiliation>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:18CAB01959EC9E2E746617E00BF56310978DC8D2</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22385</idno><idno type="url">https://api.istex.fr/document/18CAB01959EC9E2E746617E00BF56310978DC8D2/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002F25</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists</title><author><name sortKey="Andersohn, Frank" sort="Andersohn, Frank" uniqKey="Andersohn F" first="Frank" last="Andersohn">Frank Andersohn</name><affiliation><mods:affiliation>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Garbe, Edeltraut" sort="Garbe, Edeltraut" uniqKey="Garbe E" first="Edeltraut" last="Garbe">Edeltraut Garbe</name><affiliation><mods:affiliation>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-01-15">2009-01-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="129">129</biblScope><biblScope unit="page" to="133">133</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">18CAB01959EC9E2E746617E00BF56310978DC8D2</idno><idno type="DOI">10.1002/mds.22385</idno><idno type="ArticleID">MDS22385</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>adverse drug reaction reporting systems</term><term>adverse effects</term><term>dopamine agonists</term><term>fibrosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is growing evidence that the ergot‐derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot‐derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot‐derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot‐derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot‐derived dopamine agonists may not be limited to heart valves. For nonergot‐derived dopamine agonists, no drug safety signals were evident. © 2008 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Frank Andersohn MD</name><affiliations><json:string>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany</json:string></affiliations></json:item><json:item><name>Edeltraut Garbe MD, PhD</name><affiliations><json:string>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany</json:string><json:string>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonists</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>adverse effects</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>fibrosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>adverse drug reaction reporting systems</value></json:item></subject><articleId><json:string>MDS22385</json:string></articleId><language><json:string>eng</json:string></language><abstract>There is growing evidence that the ergot‐derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot‐derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot‐derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot‐derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot‐derived dopamine agonists may not be limited to heart valves. For nonergot‐derived dopamine agonists, no drug safety signals were evident. © 2008 Movement Disorder Society</abstract><qualityIndicators><score>6.74</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1083</abstractCharCount><pdfWordCount>18996</pdfWordCount><pdfCharCount>125960</pdfCharCount><pdfPageCount>34</pdfPageCount><abstractWordCount>145</abstractWordCount></qualityIndicators><title>Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists</title><genre><json:string>article</json:string></genre><host><volume>24</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>5</total><last>133</last><first>129</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22385</json:string></doi><id>18CAB01959EC9E2E746617E00BF56310978DC8D2</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/18CAB01959EC9E2E746617E00BF56310978DC8D2/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/18CAB01959EC9E2E746617E00BF56310978DC8D2/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/18CAB01959EC9E2E746617E00BF56310978DC8D2/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Frank Andersohn reports no financial support or conflicts of interest. Edeltraut Garbe reports receiving consulting fees and an unrestricted grant from Bayer Schering Healthcare AG.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists</title><author><persName><forename type="first">Frank</forename><surname>Andersohn</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Bremen Institute for Prevention Research and Social Medicine, Linzer Str. 10, D‐28359 Bremen, Germany</p></note><affiliation>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany</affiliation></author><author><persName><forename type="first">Edeltraut</forename><surname>Garbe</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany</affiliation><affiliation>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin, Germany</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-01-15"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="129">129</biblScope><biblScope unit="page" to="133">133</biblScope></imprint></monogr><idno type="istex">18CAB01959EC9E2E746617E00BF56310978DC8D2</idno><idno type="DOI">10.1002/mds.22385</idno><idno type="ArticleID">MDS22385</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>There is growing evidence that the ergot‐derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot‐derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot‐derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot‐derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot‐derived dopamine agonists may not be limited to heart valves. For nonergot‐derived dopamine agonists, no drug safety signals were evident. © 2008 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>dopamine agonists</term></item><item><term>adverse effects</term></item><item><term>fibrosis</term></item><item><term>adverse drug reaction reporting systems</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-08-01">Received</change><change when="2008-10-16">Registration</change><change when="2009-01-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/18CAB01959EC9E2E746617E00BF56310978DC8D2/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v24:1</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2009-01-15">15 January 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="210" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22385</doi><idGroup><id type="unit" value="MDS22385"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-08-01"></event><event type="manuscriptRevised" date="2008-10-11"></event><event type="manuscriptAccepted" date="2008-10-16"></event><event type="firstOnline" date="2008-11-17"></event><event type="publishedOnlineFinalForm" date="2009-01-23"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2008-11-17"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">129</numbering><numbering type="pageLast">133</numbering></numberingGroup><correspondenceTo>Bremen Institute for Prevention Research and Social Medicine, Linzer Str. 10, D‐28359 Bremen, Germany</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22385.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="19"></count><count type="wordTotal" number="3320"></count></countGroup><titleGroup><title type="main" xml:lang="en">Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists<link href="#fn5"></link></title><title type="short" xml:lang="en">Dopamine Agonists and Fibrotic Reactions</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Frank</givenNames><familyName>Andersohn</familyName><degrees>MD</degrees></personName><contactDetails><email normalForm="andersohn@bips.uni-bremen.de">andersohn@bips.uni‐bremen.de</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Edeltraut</givenNames><familyName>Garbe</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DE" type="organization"><unparsedAffiliation>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="DE" type="organization"><unparsedAffiliation>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">dopamine agonists</keyword><keyword xml:id="kwd2">adverse effects</keyword><keyword xml:id="kwd3">fibrosis</keyword><keyword xml:id="kwd4">adverse drug reaction reporting systems</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>There is growing evidence that the ergot‐derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot‐derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot‐derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot‐derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot‐derived dopamine agonists may not be limited to heart valves. For nonergot‐derived dopamine agonists, no drug safety signals were evident. © 2008 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn5"><p>Potential conflict of interest: Frank Andersohn reports no financial support or conflicts of interest. Edeltraut Garbe reports receiving consulting fees and an unrestricted grant from Bayer Schering Healthcare AG.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Dopamine Agonists and Fibrotic Reactions</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists</title></titleInfo><name type="personal"><namePart type="given">Frank</namePart><namePart type="family">Andersohn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany</affiliation><description>Correspondence: Bremen Institute for Prevention Research and Social Medicine, Linzer Str. 10, D‐28359 Bremen, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Edeltraut</namePart><namePart type="family">Garbe</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany</affiliation><affiliation>Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-01-15</dateIssued><dateCaptured encoding="w3cdtf">2008-08-01</dateCaptured><dateValid encoding="w3cdtf">2008-10-16</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">19</extent><extent unit="words">3320</extent></physicalDescription><abstract lang="en">There is growing evidence that the ergot‐derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot‐derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot‐derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot‐derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot‐derived dopamine agonists may not be limited to heart valves. For nonergot‐derived dopamine agonists, no drug safety signals were evident. © 2008 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Frank Andersohn reports no financial support or conflicts of interest. Edeltraut Garbe reports receiving consulting fees and an unrestricted grant from Bayer Schering Healthcare AG.</note><subject lang="en"><genre>Keywords</genre><topic>dopamine agonists</topic><topic>adverse effects</topic><topic>fibrosis</topic><topic>adverse drug reaction reporting systems</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>129</start><end>133</end><total>5</total></extent></part></relatedItem><identifier type="istex">18CAB01959EC9E2E746617E00BF56310978DC8D2</identifier><identifier type="DOI">10.1002/mds.22385</identifier><identifier type="ArticleID">MDS22385</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002F25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:18CAB01959EC9E2E746617E00BF56310978DC8D2
|texte= Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists
}}
| This area was generated with Dilib version V0.6.23. |  |